$120+ Billion Worldwide Immuno-Oncology Drugs Industry to 2032: Rising Number of Cancer Cases Drives the Market
13 mars 2023 12h33 HE
|
Research and Markets
Dublin, March 13, 2023 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
2023 Annual Next-Gen Immuno-Oncology Congress: Latest Updates in ADC's, mAb, BsAbs, Immune Checkpoint Inhibitors, and Cellular Therapy (Boston, MA, United States - June 22-23, 2023)
09 mars 2023 09h18 HE
|
Research and Markets
Dublin, March 09, 2023 (GLOBE NEWSWIRE) -- The "6th Annual Next-Gen Immuno-Oncology Conference" conference has been added to ResearchAndMarkets.com's offering. The 6th Annual Next Gen...
GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines
08 févr. 2023 09h00 HE
|
GeoVax, Inc.
Focused on Providing Rapid Response to Combat Emerging Infectious Threats ATLANTA, GA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
Evaxion and Pantherna announce promising preclinical mRNA vaccine data
08 févr. 2023 06h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark and HENNIGSDORF, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing...
GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers
07 févr. 2023 09h00 HE
|
GeoVax, Inc.
Phase 1/2 Trial Now Active at Stanford, Emory, and Thomas Jefferson Universities ATLANTA, GA, Feb. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028: FDA and EMA Special Drug Designations to Ignite R&D Progress
27 janv. 2023 04h58 HE
|
Research and Markets
Dublin, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The dysregulation of...
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
19 janv. 2023 08h45 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
17 janv. 2023 04h00 HE
|
AKAMPION
- Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area), Switzerland –...
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
03 janv. 2023 07h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Cancer Immunotherapy Global Market Report 2022: Spike in R&D Efforts for the Creation of Novel Oncology Treatment Bolsters 7.5% Annual Growth
29 déc. 2022 06h13 HE
|
Research and Markets
Dublin, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market by Product, Distribution Channel, Application, End Use, and by Region - Global Forecast to 2022-2033" report has been added...